Insomnia, sleep loss, and circadian sleep disturbances in mood disorders: a pathway toward neurodegeneration and neuroprogression? A theoretical review.

Insomnia circadian sleep alterations mood disorders neurodegeneration neuroprogression sleep loss

Journal

CNS spectrums
ISSN: 1092-8529
Titre abrégé: CNS Spectr
Pays: United States
ID NLM: 9702877

Informations de publication

Date de publication:
06 2022
Historique:
pubmed: 12 1 2021
medline: 26 5 2022
entrez: 11 1 2021
Statut: ppublish

Résumé

The present paper aims at reviewing and commenting on the relationships between sleep and circadian phasing alterations and neurodegenerative/neuroprogressive processes in mood disorder. We carried out a systematic review, according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, in PubMed, PsycINFO, and Embase electronic databases for literature related to mood disorders, sleep disturbances, and neurodegenerative/neuroprogressive processes in relation to (1) neuroinflammation, (2) activation of the stress system, (3) oxidative stress, (4) accumulation of neurotoxic proteins, and (5) neuroprotection deficit. Seventy articles were collectively selected and analyzed. Experimental and clinical studies revealed that insomnia, conditions of sleep loss, and altered circadian sleep may favor neurodegeneration and neuroprogression in mood disorders. These sleep disturbances may induce a state of chronic inflammation by enhancing neuroinflammation, both directly and indirectly, via microglia and astrocytes activation. They may act as neurobiological stressors that by over-activating the stress system may negatively influence neural plasticity causing neuronal damage. In addition, sleep disturbances may favor the accumulation of neurotoxic proteins, favor oxidative stress, and a deficit in neuroprotection hence contributing to neurodegeneration and neuroprogression. Targeting sleep disturbances in the clinical practice may hold a neuroprotective value for mood disorders.

Identifiants

pubmed: 33427150
doi: 10.1017/S1092852921000018
pii: S1092852921000018
doi:

Types de publication

Journal Article Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

298-308

Auteurs

Laura Palagini (L)

Department of Experimental and Clinic Medicine, Section of Psychiatry, University of Pisa, Pisa, Italy.

Pierre A Geoffroy (PA)

Département de psychiatrie et d'addictologie, AP-HP, GHU Paris Nord, DMU Neurosciences, Hopital Bichat - Claude Bernard, F-75018 Paris, France.
Université de Paris, Paris, NeuroDiderot, Inserm U1141, F-75019 Paris, France.

Mario Miniati (M)

Department of Experimental and Clinic Medicine, Section of Psychiatry, University of Pisa, Pisa, Italy.

Giulio Perugi (G)

Department of Experimental and Clinic Medicine, Section of Psychiatry, University of Pisa, Pisa, Italy.

Giovanni Biggio (G)

Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy.

Donatella Marazziti (D)

Department of Experimental and Clinic Medicine, Section of Psychiatry, University of Pisa, Pisa, Italy.

Dieter Riemann (D)

Department of Psychiatry and Psychotherapy, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH